Skip to main
  1. Stocks
  2. Heron Therapeutics
  3. Forecast
HRTX

Heron Therapeutics (HRTX) Stock Forecast & Price Target

Heron Therapeutics (HRTX) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Heron Therapeutics is supported by strong clinical results from Exparel, which further entrench the product as an effective post-operative pain treatment in hospitals and outpatient clinics, reinforcing demand in a large and clinically relevant market. Despite the CINVANTI patent setback creating a meaningful overhang on the cash-flow story, the company still has multiple commercial assets that can support revenue resilience and help offset near-term legal uncertainty. The key fundamental driver is ZYNRELEF execution in 2026, since successful commercialization there could meaningfully improve sentiment and underpin a recovery from depressed levels.

Bears say

Heron Therapeutics is facing a deteriorating fundamental profile because the adverse CINVANTI patent ruling has undermined the company’s largest revenue and cash-flow anchor, with management withdrawing 2026 revenue and Adjusted EBITDA guidance and pausing planned sales-force expansion. ZYNRELEF and APONVIE are growing, but 2Q26 revenue of $37.7M and Adjusted EBITDA of $3.2M still leave the company too dependent on CINVANTI, while ZYNRELEF’s sequential ramp to $11.1M remains too slow to offset potential erosion. With only $42.7M of cash and cash equivalents against about $142.7M of debt at June 30, the balance sheet and uncertain runway create meaningful liquidity and financing risk.

Heron Therapeutics (HRTX) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heron Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Heron Therapeutics (HRTX) Analyst Forecast & Price Prediction

Get the latest Heron Therapeutics (HRTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Heron Therapeutics (HRTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heron Therapeutics (HRTX) Forecast

Analysts have given Heron Therapeutics (HRTX) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Heron Therapeutics (HRTX) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heron Therapeutics (HRTX)


Heron Therapeutics (HRTX) Analyst Forecast & Price Prediction

Get the latest Heron Therapeutics (HRTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Heron Therapeutics (HRTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HRTX stock data and trends